Please try another search
Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
Jason P. Rhodes | 52 | 2017 | Independent Chairman |
Jeffrey Statland | - | 2020 | Member of Scientific Advisory Board |
Catherine Stehman-Breen | 61 | 2019 | Independent Director |
Dirk Kersten | 49 | 2018 | Independent Director |
Edward M. Hurwitz | 61 | 2018 | Independent Director |
Louis M. Kunkel | - | - | Member of Scientific Advisory Board |
Charles Thornton | - | - | Member of Scientific Advisory Board |
Carlo Incerti | 65 | 2022 | Independent Director |
David C. Lubner | 60 | 2020 | Independent Director |
Sudhir Agrawal | 70 | - | Member of Scientific Advisory Board |
Nancy C. Andrews | 66 | - | Member of Scientific Advisory Board |
Francesco Muntoni | - | 2020 | Member of Scientific Advisory Board |
John G. Cox | 61 | 2024 | CEO, President & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review